$0.420
-0.213 (-50.71%)收盤時
- High
- 0.549
- Open
- 0.549
- VWAP
- 0.45
- Vol
- 1.16M
- Mkt Cap
- 3.37M
- Low
- 0.390
- Amount
- 523.92K
- EV/EBITDA, TTM
- 0.00
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. The Company’s product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA), intravenous (IV) Tramadol (IV Tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. AJ201 is in a Phase 1b/2a clinical trial in the United States. AJ201 is designed to modify SBMA through multiple mechanisms including degradation of the abnormal AR protein and by stimulating Nrf1 and Nrf2, which are involved in protecting cells from oxidative stress, which can lead to cell death. Through its subsidiary, Baergic Bio, Inc. (Baergic), it is developing BAER-101, a high affinity, selective modulator of the gamma-aminobutyric acid (GABA).
Analyst Ratings (2)
Maxim Group
$0.75
2023-12-11
Maxim Group
2023-12-11
目標價
$0.75
Aegis Capital
$32
2023-04-03
Aegis Capital
2023-04-03
目標價
$32
HC Wainwright & Co.
$14625
2020-05-12
HC Wainwright & Co.
2020-05-12
目標價
$14625
HC Wainwright & Co.
—
2018-06-25
HC Wainwright & Co.
2018-06-25
目標價
—
估值指標
事件時間軸
資訊
8.511-06SeekingAlphaAxsome Therapeutics Purchases Baergic Bio from Avenue Therapeutics
4.503-18BenzingaDow Dips Over 200 Points; US Industrial Production Increases More than Expected
9.503-18BenzingaWhy Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
3.003-15NASDAQ.COMAVENUE THERAPEUTICS Earnings Preview: Recent $ATXI Insider Trading, Hedge Fund Activity, and More
4.011-16Business InsiderMaxim Group Remains a Buy on Avenue Therapeutics (ATXI)
ATXI FAQ — answered by Alphio AI
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. The Company’s product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA), intravenous (IV) Tramadol (IV Tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. AJ201 is in a Phase 1b/2a clinical trial in the United States. AJ201 is designed to modify SBMA through multiple mechanisms including degradation of the abnormal AR protein and by stimulating Nrf1 and Nrf2, which are involved in protecting cells from oxidative stress, which can lead to cell death. Through its subsidiary, Baergic Bio, Inc. (Baergic), it is developing BAER-101, a high affinity, selective modulator of the gamma-aminobutyric acid (GABA). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
2 analysts cover ATXI: 2 rate it Buy, 0 Hold and 0 Sell.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。